A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus First in man; Pharmacokinetics; Registrational
  • Sponsors Amgen
  • Most Recent Events

    • 24 Aug 2017 Planned End Date changed from 2 Aug 2018 to 2 Oct 2018.
    • 24 Aug 2017 Planned primary completion date changed from 29 Mar 2018 to 29 May 2018.
    • 19 Jul 2017 Planned End Date changed from 10 Jul 2018 to 2 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top